AHernando_Calvo

Thank you @myESMO for highlighting our recent publication in @eClinicalMed unveiling dowstream effects of performing #NGS in pts with advanced solid tumors enrolled in OCTANE. Very nice summary! 👇 esmo.org/oncology-news/… 👇 thelancet.com/journals/eclin…

Happening now at TAT 2026 @myESMO . Parp inh and synthetic lethality🧬Great presentations by Victoria Rodriguez and Xavi Maldonado from @vallhebron @VHIO

🚀 We took part in the kick-off meeting of the Joint Action on Personalised Cancer Medicine (JA PCM), a new EU initiative to expand access to personalised cancer care across Europe. 🔬 As partners, we lead a pilot to create a supranational Molecular Tumor Board for rare and complex cases and work on harmonising data collection. 🌎 Together, advancing personalised cancer medicine.

Phase 1 Study (NCT04429542): Ficerafusp alfa with/without pembrolizumab in advanced solid tumors. brnw.ch/21wXRcH

Thanks for the mention @CataniGreta! A true pleasure working with you under the expert guidance of @AhernandoCalvo and the rest of the @VHIO team. Thrilled to share our review on biomarkers in early-phase immunotherapy trials!

Our review on biomarker enrichment in early-phase immunotherapy trials is out in @FrontiersIn Grateful to collaborate with @dmorchon95 and especially for the mentorship and guidance of @AhernandoCalvo, who made this work possible doi.org/10.3389/fimmu.…

Happy to see this finally out! Humbled by the support from my former mentors at @pmcancercentre and Marc Oliva at @ICO_oncologia. An international collaboration including ultra-rare sinonasal cancers. 📌Now that we understand the prognostic factors, let's find druggable targets

Check out our latest review in collaboration with @VHIO @vallhebron team during my observership, funded by a @_SEOM grant. Congrats to first co-author @CataniGreta and special thanks to @AhernandoCalvo for the mentorship @IBSAL_IIS @IAF_Fleming @IJMS_MDPI mdpi.com/3343834

@dmorchon95 @VHIO @vallhebron @_SEOM @CataniGreta @IBSAL_IIS @IAF_Fleming @IJMS_MDPI Congrats @dmorchon95 and @CataniGreta for the hard work summarizing trends in IO phase 1 clinical trials! We We are thrilled to host such talented individuals during their training in Early drug development at @VHIO

@drenriquegrande !! 11 años avanzando en la oncología de precisión y aplicando la genómica al día a día! Un lujo contar con un panel de ponentes brutal !! Pero dejad que me 🤤 con mis amigos del @VHIO que se han salido como siempre! @rdienstmann @JHernando3 @AhernandoCalvo 🙌🏼👏🏼

🔬Esta semana hemos sabido que un estudio de @Genomicslab_ y la #UITM-@CaixaResearch del VHIO muestra que combinar la firma génica #VIGex con #biopsialíquida mejora la predicción de respuesta a inmunoterapia en tumores sólidos avanzados. ➕linke.to/VIGexVHIO24 #CAIMI #DIAMAV 📸 María Vila-Casadesús, @ElenaGarralda, @AnaVivancosVHIO y @AhernandoCalvo

🧑🏻‍⚕️ @AhernandoCalvo , @vallhebron, #UITM @CaixaResearch i @Genomicslab_ VHIO, rep una beca @GileadSciences per validar l’eina #VIGex com a biomarcador de resposta a la immunoteràpia en assajos de fase primerenca 👏 Enhorabona ‼️ ➕ linke.to/GileadGrant_ca…

📍Happy to share this publication @JCOPO_ASCO validating VIGex signature in the INSPIRE trial. Improved predictive performance for IO benefit was observed with VIGex+ctDNA dynamics in this international collaboration 🇨🇦 🇪🇸@pmcancercentre @VHIO @vallhebron ascopubs.org/doi/10.1200/PO…

Phase II, open-label, randomized trial of durvalumab with olaparib or cediranib in pts with pMMR CRC or pancreatic cancer at @pmcancercentre. Mentorship from Aaron Hansen and @lillian_siu and support from @PughLab @bhaibeka labs @OICR_news and others! doi.org/10.1016/j.clcc…

@cabify_espana Taxi reservado con anterioridad en Barcelona para las 7:10. Mensaje de conductor en camino llegada en 49 minutos (a las 6:50). El mismo conductor que habia aceptado mi reserva esta en curso de otro trayecto sabiendo que llegará tarde. Segunda vez en el mismo mes.

@Lawson_Eng @rayychan @CheungYT_HK @alexchan928 @ChinMelissa @pmcancercentre @PMResearch_UHN @UofT_DoM @UHN @CancerCareMASCC @SurvOncMASCC Congratulations Lawson! Brilliant career ahead

A true honor to be recognized with the Emerging Investigator Award at #MASCC24. Very grateful for the chance to contribute to survivorship and supportive care projects and ongoing support of many MASCC colleagues/mentors including @RayyChan @CheungYT_HK @alexchan928 @ChinMelissa

Findings from a first-in-human phase I study investigating IBI363 - @ESMO @AhernandoCalvo @vallhebron @VHIO @pmcancercentre oncodaily.com/84097.html #Cancer #ESMO #ESMODailyReporter #ESMOVirtualPlenary #Melanoma #OncoDaily #Oncology

📍Stay tuned for today´s session with both clinical insights and AACR expert commentary

#ESMOVirtualPlenary: Safety & efficacy of a PD-1/IL-2 bispecific antibody fusion protein show proof-of-concept on its capacity to overcome resistance to #immunotherapy in pre-treated pts & some populations w/ poor prognosis. #ESMODailyReporter 👉 ow.ly/c59250SiccM

Almost starting #ASCO24, and receiving the news that our review in new therapies (ADC, BsAbs) for H&N SCC and nasopharyngeal carcinoma is finally published in Cancer Treatment Reviews! Congrats to all co-authors! 👏#HNCSM @royalmarsdenNHS @VHIO authors.elsevier.com/a/1jA%7EQ15X3%…

@PaulJiL @royalmarsdenNHS @VHIO Congrats Pablo! Well deserved🙌